M
Mark E. Cooper
Researcher at University of Queensland
Publications - 1514
Citations - 141899
Mark E. Cooper is an academic researcher from University of Queensland. The author has contributed to research in topics: Diabetes mellitus & Diabetic nephropathy. The author has an hindex of 158, co-authored 1463 publications receiving 124887 citations. Previous affiliations of Mark E. Cooper include University of Cambridge & University of Adelaide.
Papers
More filters
Journal ArticleDOI
A promising outlook for diabetic kidney disease.
TL;DR: In 2018, consolidating evidence for renoprotective benefits was seen with respect to sodium–glucose cotransporter 2 inhibitors and glucagon-like peptide 1 agonists, which are currently being incorporated into clinical practice.
Plant breeding strategies for rainfed lowland rice in Northeast Thailand
Shu Fukai,Mark E. Cooper +1 more
Journal ArticleDOI
An approach to power station boiler and turbine life management
TL;DR: In this paper, the authors investigated the impact of fatigue and creep damage on the performance of a 500 MW coal-fired power plant with high-energy steam pipework and high temperature rotating plant, and developed procedures for both prevention of creep cavitation cracking and assessment of bore high strain fatigue life.
Journal ArticleDOI
Fatal respiratory diphtheria caused by ß-lactam–resistant corynebacterium diphtheriae
Brian M. Forde,Andrew Henderson,Andrew Henderson,E.G. Playford,E.G. Playford,David Looke,David Looke,Belinda Henderson,Catherine Watson,Jason A. Steen,Hanna E. Sidjabat,Gordon Laurie,Sharmini Muttaiyah,Graeme R. Nimmo,Guy Lampe,Helen V. Smith,Amy V. Jennison,Brad J McCall,Heidi J Carroll,Mark E. Cooper,David L. Paterson,Scott A. Beatson +21 more
TL;DR: A novel mechanism of inducible antibiotic resistance whereby isolates that appear to becarbapenem susceptible on initial testing can develop in vivo resistance to carbapenems with repeated exposure is identified.
Journal ArticleDOI
An optimized whole blood assay measuring expression and activity of NLRP3, NLRC4 and AIM2 inflammasomes.
Lev Grinstein,Kristin Endter,Christian M. Hedrich,Sören Reinke,Hella Luksch,Felix Schulze,Avril A. B. Robertson,Mark E. Cooper,Angela Rösen-Wolff,Stefan Winkler +9 more
TL;DR: A low-volume human whole blood assay facilitating the measurement of caspase-1 activation and inflammasome-related gene expression upon stimulation of the NLRP3, NLRC4 or AIM2 inflammaome is optimized and validated.